Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial

H. Goldschmidt, H. M. Lokhorst, E. K. Mai, B. van der Holt, I. W. Blau, S. Zweegman, K. C. Weisel, E. Vellenga, M. Pfreundschuh, M. J. Kersten, C. Scheid, S. Croockewit, R. Raymakers, D. Hose, A. Potamianou, A. Jauch, J. Hillengass, M. Stevens-Kroef, M. S. Raab, A. BroijlH. W. Lindemann, G. M. J. Bos, P. Brossart, M. van Marwijk Kooy, P. Ypma, U. Duehrsen, R. M. Schaafsma, U. Bertsch, T. Hielscher, Le Jarari, H. J. Salwender, P. Sonneveld

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)383-390
Number of pages8
JournalLeukemia
Volume32
Issue number2
DOIs
Publication statusPublished - 1 Feb 2018

Keywords

  • STEM-CELL TRANSPLANTATION
  • DIAGNOSED MULTIPLE-MYELOMA
  • 2ND PRIMARY MALIGNANCIES
  • RANDOMIZED-TRIAL
  • DEXAMETHASONE COMBINATION
  • INTERGROUPE FRANCOPHONE
  • MAINTENANCE TREATMENT
  • PLUS DEXAMETHASONE
  • STAGING SYSTEM
  • DELETION 17P

Cite this